Gmax Biopharm LLC, founded in 2010, specializes in the development of monoclonal antibodies (mAbs) targeting chronic kidney disease, obesity, and Type 2 Diabetes Mellitus (T2DM). The company has built a proprietary antibody development platform that enables efficient screening, humanization, and engineering of antibody candidates with excellent drugability. Gmax operates in the biopharmaceutical industry, focusing on creating breakthrough treatments for significant health issues. Their core leadership team boasts an average of 20 years of experience in multinational biopharmaceutical companies such as Amgen, BMS, and Genentech. Gmax serves a global market and engages in out-licensing and co-development opportunities to expand its reach. The company generates revenue through the development and commercialization of its proprietary antibody therapies, as well as through strategic partnerships and licensing agreements.

Keywords: antibody development, chronic kidney disease, obesity treatment, diabetes treatment, monoclonal antibodies, biopharmaceutical, GPCR targeting, drug development, global partnerships, proprietary platform.